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Article 15

Bacteriophage: an old weapon against bacteria reemployed
Strains of bacteria resistant to most available
antibiotics have raised the possibility that veterinary medicine may soon be confronted with
untreatable bacterial infections. Researchers are
looking for other treatments of such infections
and are investigating the use of bacteriophage
(phagin: Greek, to eat) to combat bacterial
infection.
Bacteriophage are small viruses that infect
bacteria and kill them by multiplying and basically filling the bacterial cell to bursting. They
don’t affect the infected host, because bacteriophage activity ceases once the bacterial cells are
killed. Bacteriophage, which exist in many varieties, do not attack bacteria indiscriminately,
they each usually attack only one specific kind.
Dr. Charles Benson, professor of microbiology, is working on utilizing bacteriophage to
treat bacterial infections in dairy cows. He has
identified several phage that work against specific organisms causing infections.
Bacteriophage were discovered accidentally

early in the 20th century by Frederick W. Twort,
working at the Brown Institution (London),
who was looking for filterable agents that were
nonpathogenic virus. He reported them in
Lancet as the filterable agent that had preferential activity against micrococci. The speculation
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V.M.D./Ph.D.program
Penn’s NIH-supported VMD-PhD program
was initiated in 1969 and is the only such program in the nation. Penn’s School of Medicine
offers an NIH-funded MD-PhD and veterinary
and medical students attend many of the same
lectures and courses and interact in research
laboratories on campus. The program is highly
competitive and each year only one or two students are admitted (although plans are in place
to expand the program). The School is providing limited, additional funds to attract more
students as there is a great need for veterinary
medical researchers at universities, in industry
and government agencies.
Since its inception, the program has graduated 47 individuals. It generally takes seven to
eight years to complete the program. In the
VMD curriculum students receive a thorough
training in the basic sciences as they relate to
veterinary medicine. They are exposed to and
involved in scientific research through the Graduate Groups at the University and can select
courses in any one of the following subjects:
biochemistry and molecular biophysics, cell and
molecular biology, epidemiology and biostatistics, genomics and computational biology,
immunology, neuroscience, parasitology, pharmacological sciences, biology, and bioengineering. They are able to participate in research

projects with outstanding scientists across the
University. The VMD-PhD students also receive
training in clinical medicine as they rotate
through the clinical services at the two hospitals.
After completion of the program, about
fifty per cent of the graduates go into internships or residencies, and the balance pursue
postdoctoral training. Of the 47 graduates of
the program, eighty-five percent are pursuing
careers in research: 26 serve on academic faculties, seven of these are chair, chief or head of a
department; six are active in the pharmaceutical industry, three as directors and two as presidents of companies; seven are postdoctoral fellows, interns, or residents; two are on clinical
faculties; one is with a government health
agency; and five are in private practice.
Currently there are 14 students in various
stages of the program. Four new students
joined the program in the 2002 academic year.
The School would like to expand the program
to at least five to six new students each year as
there is a great need for medically trained
researchers. What hampers the expansion of the
program is lack of funds, as these students need
financial support to complete the program.
Ideally, the School would like to provide full
funding for each student, and efforts are underway to secure the funds needed for this goal.

offered was that nonpathogenic viruses grew in
bacteria while the pathogenic strains grew in
animals. In 1917, Felix d’Herelle rediscovered
Twort’s lytic principle. d’Herelle had isolated his
agent from cultures of patients with bacillary
dysentery (shigellosis) and concluded that the
filterable agent was an obligate bacteriophage.
He proposed and utilized these bacteriophage as
“true microbes of immunity” in therapies. His
work continued for years up to his death in
1949. Twort, having never been seriously
involved with phage therapy nor properly credited for his initial observations, died in 1950.
Sinclair Lewis fictionalized the use of bacteriophage as a therapeutic agent in his 1926 book
entitled “Arrowsmith.”
The study of bacteriophage during the 40’s
through to present day has lead to a number of
observations that suggest reconsideration of
phage therapy might provide a mechanism for
circumventing the rising concerns about the
growing spectrum of resistance to antibiotics by
using a new approach. “In actuality, the
approach is not new but an old process to be
revisited and modified based on the discoveries
since Twort and d’Herelle presented their initial
findings,” says Dr. Benson. “There are many
advantages: to name a few, the cost of isolating
and preparing phage solutions is considerably
less than the discovery and production of
antibiotics, cost of testing the activity of the
phage against a pathogen is much lower than
defining antibiotic activity spectrum, phage are
not harmful to the animal, resistance to phage
does not impact on human health medicine as
does the developing resistance of the pathogen
in the animal to the drug and, an important factor, there are no significant withdrawal times
involved when phage are used to treat a disease
in food animals.”
Dr. Benson has treated seven cows with
Pseudomonas aeruginosa mastitis. In all
instances the mastitis infection was resolved
although experimental and collaboration difficulties prevented following the animals through
the drying-off period. More recently, Dr.
Benson has collaborated with Dr. Michaela
Kristula to evaluate and experimentally treat
Staphylococcus mastitis in cows in the Marshak
dairy herd. They have experienced success but
not to the extent that Dr. Benson had anticipated and he is working now to modify the preparation to provide Dr. Kristula with a more effective solution.
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